Early drop in protein C and antithrombin III is a predictor for the development of venoocclusive disease in patients undergoing hematopoietic stem cell transplantation

Journal of Hematotherapy and Stem Cell Research

Volumn 5, Issue 1, 1996, Pages 79-84

  Tabbara, Imad A ^a   Ghazal, Connie D ^a   Ghazal, Hassan H ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTITHROMBIN III; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; PROTEIN C; PROTEIN S; THIOTEPA;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; LIVER VENOOCCLUSIVE DISEASE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

EID: 0029738287     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.1.1996.5.79     Document Type: Article

References (22)

1. Hinterberger, W. & Shulman, H.M. Hepatic veno-occlusive disease - Liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant. 10:197, 1992.
2. Jones, R.J., Lee, K.S.K., Beschorner, W.E., et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 44:778, 1987.
3. McDonald, G.B., Hinds, M.S., Fisher, L.D., et al. Venoocclusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann. Intern. Med. 118:255, 1993.
4. Bearman, S.I., Anderson, G.L., Mori, M., et al. Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation. J. Clin. Oncol. 11:1729, 1993.
5. Shulman, H.M., McDonald, G.B., Matthews, D., et al. An analysis of hepatic Venoocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 79:1178, 1980.
6. Shulman, H.M., Gown, A.M. & Nugent, D.J. Hepatic venoocclusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am. J. Pathol. 127:549, 1987.
7. Scrobohaci, M.L., Drouet, L., Monemman, A., et al. Liver venoocclusive disease after bone marrow transplantation: Changes in coagulation parameters and endothelial markers. Thromb. Res. 65:509, 1991.
8. Gordon, B., Haire, W., Kessinger, A., et al. High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma. Bone Marrow Transplant. 8:497, 1991.
9. Haire, W.D., Gordon, B.G., Stephen, L., et al. Protein C (PC) deficiency during marrow transplantation: A frequent occurrence associated with a decrease in PC antigen and production of a dysfunctional PC molecule [Abstract]. Blood 78:288a, 1991.
10. Harper, P.L., Jarvis, J., Jennings, I., et al. Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transplant. 5:39, 1990.
11. Faioni, E.M., Krachmalnicoff, A., Bearman, S.I., et al. Naturally occurring anticoagulants and bone marrow transplantation: Plasma protein C predicts the development of venoocclusive disease of the liver. Blood 81:3458, 1993.
12. Attal, M., Huguet, F., Rubie, H., et al. Prevention of hepatic venoocclusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial. Blood 79:2834, 1992.
13. Baglin, T.P., Harper, P. & Marcus, R.E. Venoocclusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator. Bone Marrow Transplant. 5:439, 1990.
14. Bearman, S.I., Shuhart, M.C., Hinds, M.S., et al. Recombinant human tissue plasminogen activator for the treatment of established severe venoocclusive disease of the liver after bone marrow transplantation. Blood 80:2458, 1992.
15. Bearman, S.I., Appelbaum, F.R., Buckner, C.D., et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J. Clin. Oncol. 6:1562, 1988.
16. Bearman, S.I., Appelbaum, F.R., Back, A., et al. Regimenrelated toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J. Clin. Oncol. 7:1288, 1989.
17. Essell, J.H., Thompson, J.N., Harman, G.S., et al. Marked increased in venoocclusive disease of the liver associated with methotrexate use for graft-versus-host-disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 79:2784, 1992.
18. Haire, W.D., Lieberman, R.P., Edney, J., et al. Hickman catheter-induced thoracic vein thrombosis: Frequency and long-term sequelae in patients receiving high-dose chemotherapy and marrow transplantation. Cancer 66:900, 1990.
19. Patchell, R. A., White, C.L., Clark, A.W., et al. Nonbacterial thrombotic endocarditis in bone marrow transplant patients. Cancer 55:631, 1985.
20. Diez-Martin, J.L., Haberman, T.M., Gastineau, D.A., et al. Nonbacterial thrombotic endocarditis in autologous bone marrow transplantation. Am. J. Med. 85:742, 1988.
21. Stephens, L.C., Haire, W.D. & Ruby, E.I. Pharmacokinetics of anti-thrombin III concentrate during bone marrow transplantation. Bone Marrow Transplant. 15:505, 1995.
22. Haire, W.D., Ruby, E.I., Gordon, B.G., et al. Antithrombin III levels predict for multi-organ dysfunction in hematopoietic stem cell transplantation (HSCT) [Abstract]. 6th International Symposium, Supportive Care in Cancer, 1994.